Abstract YO14
Case summary
Urachal cancer is a rare neoplasm which represents approximately 0.5-2% of all bladder cancer.
A 52 year old Filipino male presented with painless hematuria. Physical examination was unremarkable. KUB ultrasound showed a bladder mass so Cystoscopy–TUR was done. Histopathology revealed adenocarcinoma with involvement of muscularis propria. He was advised surgery but did not consent. Contrast-enhanced abdominal computed tomography (CT) showed a well-defined, slightly wall enhancing, midline infraumbilical complex soft tissue mass measuring 3.6x4.0x5.1cm in the anterosuperior aspect of the urinary bladder extending to the urachus with no communication to the umbilicus. Cystoscopy, Partial Cystectomy with Umbilectomy was done. Intra-operative findings: bladder mass at the dome approximately 2-3cm in size, necrotic tissue with band of tissue directly connected to the umbilicus. Histopathology was urachal adenocarcinoma which extends to the urinary bladder muscularis propria and perivesical tissue. He was advised close follow-up.
After one year, he started to experience difficulty initiating urine. Repeat CT scan showed: urinary bladder with an intraluminal enhancing nodule in the superoanterior wall measuring 1.5x1.7cm, irregular anterior urinary bladder wall thickening measuring 7.3x1.5cm is also noted, small anterior perivesical nodes are noted measuring 0.7x1.2 cm. Cysto-TURP of Bladder Tumor, Exploratory Laparotomy, Adhesiolysis, was done. Intra-operative findings were: smooth urethral mucosa without stenosis or stricture; pedunculated broad-based, friable, pink fleshy mass seen at the posterolateral bladder wall, measuring 5-8 cm in greatest diameter; flat erythematous lesion measuring 2cm noted at bladder dome; muiltiple nodularities along peritoneum with some attached to ileal loops. Specimen’s pathology reported adenocarcinoma and peritoneal nodularities were metastatic adenocarcinoma; morphological features favored the diagnosis of urachal adenocarcinoma. CT scan of the Chest showed innumerable varisized non-calcified parenchymal, fissural, and subpleural nodules scattered in both lungs which were worrisome for metastasis. The patient has received systemic chemotherapy with Cisplatin and Fluorouracil.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract